In clinical setting, some studies were published about treatments combining radiation therapy and angiogenic inhibitors. The main study was conducted for rectal carcinoma (9), showing a safety profile of a combined scheme of bevacizumab and capecitabine in association with pre-operative pelvic irradiation. Efficacy data are encouraging (downstaging for 9 /11 patients, histological regression for 5 patients). Similar conclusions may be drawn from another study performed in patients with unresectable pancreatic carcinoma treated with a radio-chemotherapy including bevacizumab, leading to an objective response for 9 patients (20 %), 4 of them were operable at the end of radio-chemotherapy.